In 2012, the United States Preventative Services Task Force (USPSTF) stopped recommending PSA (prostate-specific antigen) testing to screen for prostate cancer because the group thought it was more harmful than beneficial. Now, the USPSTF has issued a new statement updating its 2012 recommendations.
The statement and a medical review were published in the Journal of the American Medical Association (JAMA). According to the new guidelines, men between ages 55 to 69 should talk to their health care provider about the risks and benefits of PSA testing and then make their own decision about whether to have the test or not.
These updated recommendations are largely based on the European Randomized Study of Screening for Prostate Cancer trial conducted in 2014, which showed that screening for prostate cancer using PSA testing can prevent one cancer-related death and three cases of metastatic disease for every 1,000 men between 55 and 69 who are screened.
Sourced from: JAMA